IRS1, KCNJ11, PPARγ2 and HNF-1α: Do amino acid polymorphisms in these candidate genes support a shared aetiology between type 1 and type 2 diabetes?

Diabetes, Obesity and Metabolism

Volumn 8, Issue 1, 2006, Pages 75-82

  Johansen, Anders ^a   Jensen, D P ^a   Bergholdt, R ^a   Mortensen, H B ^b,c   Pociot, F ^a   Nerup, J ^a   Hansen, T ^a   Pedersen, O ^a,d  

^a STENO DIABETES CENTER   (Denmark)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d AARHUS UNIVERSITY   (Denmark)

Author keywords

Gene; Genetics; HNF 1alpha; Insulin; Insulin secretion; Insulin sensitivity; IRS1; Kir6.2; Polymorphisms; Type 2 diabetes; Type1 diabetes

Indexed keywords

ALANINE; ARGININE; GLUTAMIC ACID; GLYCINE; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; INSULIN RECEPTOR SUBSTRATE 1; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; LYSINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PROLINE; VALINE; AMINO ACID; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; INSULIN; INSULIN RECEPTOR SUBSTRATE 1 PROTEIN; INSULIN RECEPTOR SUBSTRATE-1 PROTEIN; INWARDLY RECTIFYING POTASSIUM CHANNEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOPROTEIN;

ARTICLE; CONTROLLED STUDY; DENMARK; DIABETOGENESIS; FAMILY STUDY; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; INHERITANCE; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MULTIPLEX POLYMERASE CHAIN REACTION; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; ADOLESCENT; ADULT; CHILD; DIABETES MELLITUS; FAMILY HEALTH; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; INFANT; METABOLISM; METHODOLOGY; PARENT; PRESCHOOL CHILD; SIBLING;

ADOLESCENT; ADULT; AMINO ACIDS; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FAMILY HEALTH; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HETEROZYGOTE; HLA-DR3 ANTIGEN; HLA-DR4 ANTIGEN; HUMANS; INFANT; INSULIN; PARENTS; PHOSPHOPROTEINS; POLYMORPHISM, GENETIC; POTASSIUM CHANNELS, INWARDLY RECTIFYING; PPAR GAMMA; SIBLINGS;

EID: 33645988557     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2005.00471.x     Document Type: Article

References (55)

1. Atkinson MA, Eisenbarth GS. Type 1 diabetes: New perspectives on disease pathogenesis and treatment. Lancet 2001; 358: 221-229.
2. Hirschhorn JN. Genetic epidemiology of type 1 diabetes. Pediatr Diabetes 2003; 4: 87-100.
3. Florez JC, Hirschhorn J, Altshuler D. The inherited basis of diabetes mellitus: Implications for the genetic analysis of complex traits. Annu Rev Genomics Hum Genet 2003; 4: 257-291.
4. Mathis D, Vence L, Benoist C. Beta-Cell death during progression to diabetes. Nature 2001;414: 792-798.
5. Naik RG. Latent autoimmune diabetes in adults (LADA). Rev Endocrine Metab Disorders 2003; 4: 233-241.
6. Dahlquist G, Blom L, Tuvemo T, Nystrom L, Sandstrom A, Wall S. The Swedish childhood diabetes study - results from a nine year case register and a one year case-referent study indicating that type 1 (insulin-dependent) diabetes mellitus is associated with both type 2 (non-insulin-dependent) diabetes mellitus and autoimmune disorders. Diabetologia 1989; 32: 2-6.
7. Carel JC, Boitard C, Bougneres PF. Decreased insulin response to glucose in islet cell antibody-negative siblings of type 1 diabetic children. J Clin Invest 1993; 92: 509-513.
8. Li H, Lindholm E, Almgren P et al. Possible human leukocyte antigen-mediated genetic interaction between type 1 and type 2 Diabetes. J Clin Endocrinol Metab 2001; 86: 574-582.
9. Elbein SC, Hoffman MD, Mayorga RA, Barrett KL, Leppert M, Hasstedt S. Do non-insulin-dependent diabetes mellitus (NIDDM) and insulin-dependent diabetes mellitus (IDDM) share genetic susceptibility loci? An analysis of putative IDDM susceptibility regions in familial NIDDM. Metabolism 1997; 46: 48-52.
10. Tuomilehto-Wolf E, Tuomilehto J, Hitman GA et al. Genetic susceptibility to non-insulin dependent diabetes mellitus and glucose intolerance are located in HLA region. BMJ 1993; 307: 155-159.
11. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-110.
12. Efanova IB, Zaitsev SV, Zhivotovsky B, Kohler M, Orrenius S, Berggren PO. Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular ca2+ concentration. J Biol Chem 1998; 273: 33501-33507.
13. Federici M, Hribal M, Perego L et al. High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: A potential role for regulation of specific Bcl family genes toward an apoptotic cell death program. Diabetes 2001; 50: 1290-1301.
14. Donath MY, Gross DJ, Cerasi E, Kaiser N. Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes. Diabetes 1999; 48: 738-744.
15. Donath MY, Storling J, Maedler K, Mandrup-Poulsen T. Inflammatory mediators and islet beta-cell failure: A link between type 1 and type 2 diabetes. J Mol Med 2003; 81: 455-470.
16. Almind K, Bjorbaek C, Vestergaard H, Hansen T, Echwald S, Pedersen O. Aminoacid polymorphisms of insulin receptor substrate-1 in non-insulin-dependent diabetes mellitus. Lancet 1993; 342: 828-832.
17. Hitman GA, Hawrami K, McCarthy MI et al. Insulin receptor substrate-1 gene mutations in NIDDM; implications for the study of polygenic disease. Diabetologia 1995; 38: 481-486.
18. Jellema A, Zeegers MP, Feskens EJ, Dagnelie PC, Mensink RP. Gly972Arg variant in the insulin receptor substrate-1 gene and association with Type 2 diabetes: A meta-analysis of 27 studies. Diabetologia 2003; 46: 990-995.
19. Almind K, Inoue G, Pedersen O, Kahn CR. A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. J Clin Invest 1996; 97: 2569-2575.
20. Stumvoll M, Fritsche A, Volk A et al. The Gly972Arg polymorphism in the insulin receptor substrate-1 gene contributes to the variation in insulin secretion in normal glucose-tolerant humans. Diabetes 2001; 50: 882-885.
21. Clausen JO, Hansen T, Bjorbaek C et al. Insulin resistance: Interactions between obesity and a common variant of insulin receptor substrate-1. Lancet 1995; 346: 397-402.
22. Zhang Y, Wat N, Stratton IM et al. UKPDS 19: Heterogeneity in NIDDM. Separate contributions of IRS-1 and beta 3-adrenergic-receptor mutations to insulin resistance and obesity respectively with no evidence for glycogen synthase gene mutations. UK Prospective Diabetes Study. Diabetologia 1996; 39: 1505-1511.
23. Baroni MG, Arca M, Sentinelli F et al. The G972R variant of the insulin receptor substrate-1 (IRS-1) gene, body fat distribution and insulin-resistance. Diabetologia 2001; 44: 367-372.
24. Federici M, Hribal ML, Ranalli M et al. The common Arg972 polymorphism in insulin receptor substrate-1 causes apoptosis of human pancreatic islets. FASEB J 2001; 15: 22-24.
25. Federici M, Petrone A, Porzio O et al. The Gly972->Arg IRS-1 variant is associated with type 1 diabetes in continental Italy. Diabetes 2003; 52: 887-890.
26. Morrison VA, Onengut-Gumuscu S, Concannon P. A functional variant of IRS1 is associated with type 1 diabetes in families from the US and UK. Mol Genet Metab 2004; 81: 291-294.
27. Effychi C, Howson JM, Barrat BJ et al. Analysis of the type 2 diabetes-associated single nucleotide polymorphisms in the genes IRS1, KCNJ11, and PPARG2 in type 1 diabetes. Diabetes 2004; 53: 870-873.
28. Aguilar-Bryan L, Bryan J. Molecular biology of adenosine triphosphate-sensitive potassium channels. Endocr Rev 1999; 20: 101-135.
29. Schwanstecher C, Meyer U, Schwanstecher MK (IR) 6.2 polymorphism predisposes to type 2 diabetes by inducing overactivity of pancreatic beta-cell ATP-sensitive K(+) channels. Diabetes 2002; 51: 875-879.
30. Parikh H, Groop L. Candidate genes for type 2 diabetes. Rev Endocrine Metabolic Disorders 2004; 5: 151-176.
31. Gloyn AL, Weedon MN, Owen KR et al. Large-scale association studies of variants in genes encoding the pancreatic {beta}-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes 2003; 52: 568-572.
32. Nielsen EM, Hansen L, Carstensen B et al. The E23K Variant of Kir6.2 associates with impaired post-OGTT serum insulin response and increased risk of type 2 diabetes. Diabetes 2003; 52: 573-577.
33. Yamagata K, Oda N, Kaisaki PJ et al. Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature 1996; 384: 455-458.
34. Yamagata K, Nammo T, Moriwaki M et al. Overexpression of dominant-negative mutant hepatocyte nuclear factor-1{alpha} in pancreatic {beta}-cells causes abnormal islet architecture with decreased expression of E-cadherin, reduced {beta}-cell proliferation, and diabetes. Diabetes 2002; 51: 114-123.
35. Urhammer SA, Fridberg M, Hansen T et al. A prevalent amino acid polymorphism at codon 98 in the hepatocyte nuclear factor-1alpha gene is associated with reduced serum C-peptide and insulin responses to an oral glucose challenge. Diabetes 1997; 46: 912-916.
36. Urhammer SA, Hansen T, Ekstrom CT, Eiberg H, Pedersen O. The Ala/Val98 polymorphism of the hepatocyte nuclear factor-1{alpha} gene contributes to the interindividual variation in serum C-peptide response during an oral glucose tolerance test. Evidence from studies of 231 glucose-tolerant first degree relatives of type 2 diabetic probands. J Clin Endocrinol Metab 1998; 83: 4506-4509.
37. Jackson AE, Cassell PG, North BV et al. Polymorphic variations in the neurogenic differentiation-1, neurogenin-3, and hepatocyte nuclear factor-1{alpha} genes contribute to glucose intolerance in a South Indian population. Diabetes 2004; 53: 2122-2125.
38. Kubota N, Terauchi Y, Miki H et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 1999; 4: 597-609.
39. Rosen ED, Sarraf P, Troy AE et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 1999; 4: 611-617.
40. Deeb SS, Fajas L, Nemoto M et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20: 284-287.
41. Beales PE, Pozzilli P. Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse: Implications for human type 1 diabetes. Diabetes Metab Res Rev 2002; 18: 114-117.
42. Pociot F, Norgaard K, Hobolth N, Andersen O, Nerup J. A nationwide population-based study of the familial aggregation of type 1 (insulin-dependent) diabetes mellitus in Denmark. Danish Study Group of Diabetes in Childhood. Diabetologia 1993; 36: 870-875.
43. Lorenzen T, Pociot F, Stilgren L et al. Predictors of IDDM recurrence risk in offspring of Danish IDDM patients. Danish IDDM Epidemiology and Genetics Group. Diabetologia 1998; 41: 666-673.
44. Nerup J, Pociot F. European Consortium for IDDM Studies A genomewide scan for type 1-diabetes susceptibility in Scandinavian families. Identification of new loci with evidence of interactions. Am J Human Genet 2001; 69: 1301-1313.
45. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
46. Bergholdt R, Larsen ZM, Andersen NA et al. Characterization of new polymorphisms in the 5′ UTR of the human interleukin-1 receptor type 1 (IL1R1) gene: Linkage to type 1 diabetes and correlation to IL-1RI plasma level. Genes Immun 2000; 1: 495-500.
47. Spielman RS. Transmission test for linkage disequilibrium. The insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am J Human Genet 1993; 52: 506-516.
48. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: A key component of the obesity-diabetes link. Diabetes 1994; 43: 1271-1278.
49. Hofmann C, Lorenz K, Braithwaite SS et al. Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance. Endocrinology 1994; 134: 264-270.
50. Giorgini AE, Beales PE, Mire-Sluis A, Scott D, Liddi R, Pozzilli P. Troglitazone exhibits immunomodulatory activity on the cytokine production of activated human lymphocytes. Horm Metab Res 1999; 31: 1-4.
51. Buchanan TA, Xiang AH, Peters RK et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002; 51: 2796-2803.
52. Durbin RJ. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab 2004; 6: 280-285.
53. Masugi J, Tamori Y, Mori H, Koike T, Kasuga M. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun 2000;268: 178-182.
54. Jacob S. The PPARgamma2 polymorphism pro12Ala is associated with better insulin sensitivity in the offspring of type 2 diabetic patients. Hormone Metab Res 2000; 32: 413-416.
55. Ek J. Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant caucasians. Diabetologia 2001;44: 1170-1176.